Skip to main content
. 2017 Jun 2;2(11):e90853. doi: 10.1172/jci.insight.90853

Figure 3. Efficient infection of engineered human liver tissues with patient-derived HCV inoculum and assessment of antiviral activity of sofosbuvir.

Figure 3

Parallel cultures of fetal total liver cells (FTLCs) in Col-I ICC were inoculated with hepatitis C virus (HCV) inoculum at day 9 after seeding. At 4 hours after inoculation, virus was removed, cultures were washed 5 times with PBS, and fresh medium was added; samples were collected before and after wash at the indicated intervals for qPCR HCV RNA analysis. One set of cultures was treated with 1 μM sofosbuvir at day 11 after inoculation (red tracing; drug treatment indicated by arrow), while another set was treated with vehicle alone (black tracing). Data are mean ± SD with 5 biological replicates.